Clinical trial
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic…
NCT00210457 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00210457 |
|---|---|
| Title | Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients |
| Official title | Phase III, Multicentre, Open Study to Assess the Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Previously Treated or Not by Somatostatin Analogues. |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Lanreotide (Autogel formulation) |
| Enrollment | 63 |
| Start date | Sep 1, 2000 |
| Primary completion | Jul 15, 2002 |
| Completion | Jul 15, 2002 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 31, 2020 |
| Countries | France, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: